RenovoRx, Inc. (RNXT) - 10-K Filing Summary
Business Context and Reporting Period
Company: RenovoRx, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: RenovoRx is a life sciences company developing targeted oncology therapies. Its primary commercial product is the RenovoCath, an FDA-cleared local drug-delivery device utilizing the Trans-Arterial Micro-Perfusion (TAMP) platform. The company is also advancing IAG, a drug-device combination product (intra-arterial gemcitabine delivered via RenovoCath) for the treatment of Locally Advanced Pancreatic Cancer (LAPC) in a Phase III clinical trial (TIGeR-PaC).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $1.12 million | $0.04 million |
| Cost of Revenue | $0.33 million | $0 |
| Gross Profit | $0.80 million | $0.04 million |
| Net Loss | $(11.17) million | $(8.81) million |
| Accumulated Deficit | $(61.39) million | $(50.22) million |
| Cash and Cash Equivalents (Dec 31, 2025) | $7.02 million | $7.15 million |
| Operating Cash Flow | $(10.97) million | $(9.13) million |
Note: Cash balance as of March 23, 2026, increased to approximately $13.0 million following a $10.0 million private placement in March 2026.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 2,512% year-over-year, driven by the first full year of commercial sales of the RenovoCath device. Sales were generated from U.S. cancer centers initiating repeat orders and new institutions adopting the device.
- Commercial Expansion: As of February 2026, 12 U.S. cancer centers were utilizing RenovoCath commercially, with 21 additional centers evaluating or preparing for activation. This represents a tripling of the near-term commercial pipeline since Q1 2025.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 41% to $7.04 million, primarily due to the launch of a full sales and marketing team in late 2025 and increased professional services. Research and Development (R&D) expenses increased 4% to $6.27 million, driven by non-recurring engineering costs for next-generation devices and clinical trial activities.
- Warrant Liability: The company recognized a gain of $0.92 million from the change in fair value of common stock warrant liability, a decrease from the $1.77 million gain in 2024.
Guidance, Outlook, and Risks
Clinical Outlook: The Phase III TIGeR-PaC trial for IAG is ongoing. As of March 24, 2026, 104 patients had been randomized with 72 events (deaths) occurring. Enrollment is expected to complete by mid-2026, with final data anticipated in 2027. The first interim analysis showed a 6-month median overall survival benefit and a >65% reduction in adverse events compared to standard of care.
Commercial Outlook: Management expects revenue expansion in 2026 as the sales team scales and more centers activate. The company estimates a peak annual U.S. sales potential of approximately $400 million for RenovoCath.
Liquidity and Capital: The company raised $10.0 million in a private placement in March 2026. Management believes current cash resources are sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring net losses until IAG receives FDA approval or RenovoCath generates sufficient revenue.
Key Risks:
- Nasdaq Compliance: The company received notice of non-compliance with the Nasdaq minimum bid price requirement ($1.00 per share) as of December 31, 2025. It has until June 2026 to regain compliance or risk delisting.
- Internal Controls: Material weaknesses in internal control over financial reporting were identified in 2025 (though management states remediation was completed by year-end). Weaknesses included inadequate accounting policies, inexperienced personnel, and lack of segregation of duties.
- Regulatory Approval: No assurance exists that the TIGeR-PaC trial will meet endpoints or that the FDA will approve IAG.
Investor Verification Checklist
- Nasdaq Status: Verify if the company has regained compliance with the $1.00 minimum bid price requirement by June 2026 to avoid delisting.
- Cash Runway: Confirm the utilization of the $10.0 million raised in March 2026 and the timeline for potential future capital raises given the $11.2 million annual burn rate.
- Clinical Trial Progress: Monitor enrollment rates and event counts for the TIGeR-PaC Phase III trial, as final data is not expected until 2027.
- Commercial Adoption: Track the conversion rate of the 21 centers currently evaluating RenovoCath into active commercial customers.
- Internal Controls: Review future filings to ensure the material weaknesses in financial reporting remain remediated and do not recur.